RE-BVS – Piemonte Repository

Sfoglia per AUTORE
RULLI E
Collezione ASL Biella

Items : 9

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. in British journal of cancer / Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9.

2023
AOU Città della Salute di Torino
ASL Biella

Poveda A; Tsibulak I; Wimberger P; Heinzelmann-Schwarz V; Westermann A; Aglietta M; Arcangeli V; Zamagni C; Bologna A; Benedetti Panici P; Zola P; De Giorgi U; DeCensi A; Tognon G; Rubio-Pérez MJ; Pardo B; Romeo M; Tasca G; Funari G; Iglesias M; Biagioli E; Barretina-Ginesta MP; Deryal M; Mirza MR; Fossati R; Herbertson R; Riniker S; Nyvang GB; Chekerov R; et alii...

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.

2020
ASL Biella

Sobrero A; Frontini L; Bergamo F; Verusio C; Lazzarelli S; Turci D; Bramati A; Biondi E; Foltran L; Nicolini M; Ricci V; Barni S; Sozzi P; Veltri E; Bagaloni I; Mucciarini C; Labianca R; Ionta MT; Zagonel V; Pella N; Ronzoni M; Massidda B; Lonardi S; Rulli E; Magnani M; Galli F; Graziano F; Galli F; Ruzzo A; et alii...

Oral prolonged-release Oxycodone-Naloxone: analgesic response, safety profile, and factors influencing the response in advanced cancer patients. in Pain practice : the official journal of World Institute of Pain / Pain Pract. 2019 Mar 27. doi: 10.1111/papr.12784.

2019
ASL Biella

Corsi N; Marabese M; Pacchioni M; Crispino C; Bortolussi R; Clerico M; Mistretta R; Dauri M; Cartoni C; Di Marco P; De Santis S; Schiavon S; Cavanna L; Azzarello G; Roberto A; Rulli E; Legramandi L; Iorno V; Corli O;

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.

2019
ASL Biella

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. in British journal of cancer / Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

2017
ASL Biella

Menghi M; Magnani M; Verusio C; Frontini L; Sobrero A; Bergamo F; Lazzarelli S; Biondi E; Bramati A; Turci D; Nicolini M; Foltran L; Ricci V; Sozzi P; Barni S; Bagaloni I; Veltri E; Ionta MT; Labianca R; Mucciarini C; Ronzoni M; Massidda B; Zagonel V; Pella N; Lonardi S; Galli F; Rulli E; Galli F; Ruzzo A; et alii...

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: A pharmacogenetic ancillary study to TOSCA trial in Annals of Oncology

2017
ASL Biella
AO Ordine Mauriziano

Ruzzo A; Galli F; Rulli E; Lonardi S; Zagonel V; Ronzoni M; Ionta MT; Pella N; Mucciarini C; Labianca R; Veltri E; Sozzi P; Barni S; Nicolini M; Biondi E; Bramati A; Turci D; Buscaglia M; Magnani M; Graziano F; Tampellini M; Falco E; De Rosa G; Montarolo F; Dacomo R; Baratelli C; Sperti E; Di Maio M; Scagliotti GV; et alii...

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial in Annals of oncology : official journal of the European Society for Medical Oncology

2017
ASL Biella

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. in Scientific reports / Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

2014
ASL Biella

Magnani M; Frontini L; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Turci D; Bramati A; Biondi E; Ricci V; Foltran L; Nicolini M; Veltri E; Sozzi P; Barni S; Zagonel V; Pella N; Mucciarini C; Ionta MT; Labianca R; Lonardi S; Ronzoni M; Massidda B; Rulli E; Floriani I; Galli F; Giacomini E; Graziano F; Galli F; et alii...

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer in Annals of Oncology

2014
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 2

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Rulli E; Cropalato Di Tullio M; et alii...